Evidence map›Paper›PMID 40755520›Full record

ArticleThe Canadian journal of hospital pharmacy2025

Implementation of Piperacillin-Tazobactam Continuous Infusions for Critically Ill Patients: A Single-Centre Retrospective Chart Review.

Kylie Landry, Meghan MacKenzie, Sarah Burgess, Paul Bonnar, Yahya Shabi, Glenn Patriquin, Karolynn Holland, Volker Eichhorn

Abstract read
In one paragraph

Article in The Canadian journal of hospital pharmacy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kylie Landry, BScPharm, ACPR, is a Clinical Pharmacist - Internal Medicine and Critical Care with the Pharmacy Department, Nova Scotia Health, Central Zone, Halifax, Nova Scotia.
Meghan MacKenzie, BScPharm, ACPR, PharmD, is the Clinical Coordinator Critical Care, Emergency Medicine, with the Pharmacy Department, Nova Scotia Health, Central Zone, and an Assistant Professor, College of Pharmacy, Dalhousie University, Halifax, Nova Scotia.
Sarah Burgess, BScPharm, ACPR, PharmD, is a Clinical Pharmacist - Infectious Diseases with the Pharmacy Department, Nova Scotia Health, Central Zone, Halifax, Nova Scotia.
Paul Bonnar, MD, FRCPC, is an Assistant Professor - Infectious Diseases with the Division of Infectious Diseases, Department of Medicine, Nova Scotia Health, Central Zone, Halifax, Nova Scotia.
Yahya Shabi, MBBS, FRCPC, was, at the time of this study, a Clinical Fellow with the Division of Microbiology, Department of Pathology and Laboratory Medicine, Nova Scotia Health, Central Zone, Halifax, Nova Scotia. He is now an Assistant Professor with the Department of Microbiology and Clinical Parasitology, College of Medicine, King Khalid University, Abha, Saudi Arabia.
Glenn Patriquin, MD, MSc, FRCPC, is an Associate Professor with the Division of Microbiology, Department of Pathology and Laboratory Medicine, Nova Scotia Health, Central Zone, Halifax, Nova Scotia.
Karolynn Holland, BSc, BScN, is the Critical Care Quality Leader with the Department of Critical Care, Nova Scotia Health, Central Zone, Halifax, Nova Scotia.
Volker Eichhorn, MD, is an Anesthetist/Attending Physician - Critical Care with the Department of Critical Care, Nova Scotia Health, Central Zone, Halifax, Nova Scotia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: In critically ill patients, pharmacokinetic variability can lead to inadequate antimicrobial concentrations. Antimicrobial resistance to β-lactam antibiotics is increasing among the nonfermenting gram-negative bacilli (NFGNB). Current guidelines recommend optimizing β-lactam pharmacokinetics/pharmacodynamics with prolonged infusion of these antibiotics. In 2019, a protocol for continuous infusion of piperacillin-tazobactam (P/T) was implemented in 2 intensive care units (ICUs) as a quality improvement initiative. Objectives: The primary objective was to describe and evaluate implementation of the practice change to continuous infusion of P/T. The secondary objectives were to describe ICU mortality and length of stay (LOS), identify safety incidents related to the protocol, and determine the prevalence of NFGNB and associated minimum inhibitory concentrations of P/T. Methods: This single-centre retrospective study involved a convenience sample of 200 patients who received 2 or more doses of P/T during an ICU admission between October 2020 and October 2022. Data on drug administration, characteristics of the hospital stay, and patient outcomes were collected from patients' digital records and the Critical Care Database of the study institution. Eight criteria for successful implementation of the protocol were established, with implementation deemed successful if at least 6 of these criteria were met. Results: Implementation of the continuous-infusion protocol was successful for 156 (78.0%) of the 200 ICU patients, 41 (20.5%) of the patients died during the ICU admission, and the median LOS in the ICU was 4.9 (interquartile range 2.4-10.7) days. No safety incidents were identified. The prevalence of NFGNB was 3.1% for all ICU patients over the 2-year study period. Conclusions: Implementation of the continuous-infusion protocol was successful in most patients. Areas for improvement include editing the order set, providing interprofessional education, and enhancing interprofessional collaboration.

Indexed as

continuous infusion, piperacillinperfusion continuepipéracilline-tazobactamsoins intensifstazobactam, critical care

Identifiers

PMID40755520
PMCPMC12316688

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.